COSCO SHIP PORT (01199) released its 2025 performance, with a net profit attributable to shareholders of approximately $312 million, representing a year-on-year increase of 1.1%.
China Merchants Port (01199) announced its full-year performance for 2025, with revenue of 1.669 billion US dollars, a year-on-year increase of 11.0%. The company's equity holders are expected to have a profit of approximately 312 million US dollars, a year-on-year increase of 1.1%. Basic earnings per share were 8.14 US cents. It is proposed to distribute a second interim dividend for the year ending December 31, 2025, of 10.2 Hong Kong cents per ordinary share, replacing the final dividend.
COSCO SHIP PORT (01199) announces its full-year performance for 2025, with revenue of 1.669 billion USD, representing a year-on-year growth of 11.0%. The company's shareholders' attributable profit is approximately 312 million USD, an increase of 1.1% year-on-year. Basic earnings per share are 8.14 cents. The company plans to distribute a second interim dividend for the year ending December 31, 2025, of 10.2 Hong Kong cents per share, instead of a final dividend.
In 2025, the Group's total throughput increased by 6.2% year-on-year. The total throughput of the Group's controlled terminal companies increased by 1.8% year-on-year, accounting for 21.7% of the Group's total throughput. The total throughput of non-controlled terminal companies increased by 7.5% year-on-year, representing 78.3% of the Group's total throughput.
Related Articles
.png)
Zhejiang Vie Science & Technology (002590.SZ) and its subsidiary plan to increase capital to approximately 80 million yuan for Wanan Zhisheng to help its business development.

CN ENGY STORAGE (01143): Wang Qi resigns as executive director

Zhejiang Huahai Pharmaceutical (600521.SH): HB0025 Injection Initiates Phase III Clinical Trial for Endometrial Cancer.
Zhejiang Vie Science & Technology (002590.SZ) and its subsidiary plan to increase capital to approximately 80 million yuan for Wanan Zhisheng to help its business development.
.png)
CN ENGY STORAGE (01143): Wang Qi resigns as executive director

Zhejiang Huahai Pharmaceutical (600521.SH): HB0025 Injection Initiates Phase III Clinical Trial for Endometrial Cancer.

RECOMMEND

European Carmakers Embrace China: Under Technology And Cost Pressure, Stellantis And Mercedes Seek Partnerships With Chinese Automakers
17/03/2026

HKEX Listing Mechanism Reform Revisited: How To Balance New Favorites And Established Names
17/03/2026

International Oil Prices Plunge Boosts U.S. Stocks; Morgan Stanley Chief Says Market Correction Nearing End
17/03/2026


